LeadIQ logo
Learn more at LeadIQ.com

Insights

Innovative Therapies ImmusanT is advancing a novel therapeutic vaccine, Nexvax2, targeting gluten tolerance in celiac disease patients, providing opportunities for partnerships in immunotherapy offerings and autoimmune disease management.

Autoimmune Focus The company's development of vaccines for HLA-associated autoimmune diseases like type 1 diabetes suggests potential expansion into broader autoimmune markets and collaborations with specialty healthcare providers.

Clinical Development Stage With plans for Phase 2 clinical trials of Nexvax2, there are sales opportunities in vaccine manufacturing, clinical testing services, and related diagnostics for celiac disease monitoring.

Funding & Growth Backed by $52M in funding, ImmusanT demonstrates strong investor confidence, highlighting potential for partnership or investment in early-stage biotech collaborations and supportive healthcare ecosystems.

Market Positioning Focusing on autoimmune diseases with a targeted immunotherapy platform positions ImmusanT as a valuable partner for pharmaceutical companies exploring innovative autoimmune treatment pipelines and diagnostic tools.

ImmusanT, Inc. Tech Stack

ImmusanT, Inc. uses 8 technology products and services including Font Awesome, yepnope.js, OWL Carousel, and more. Explore ImmusanT, Inc.'s tech stack below.

  • Font Awesome
    Font Scripts
  • yepnope.js
    Javascript Frameworks
  • OWL Carousel
    Javascript Libraries
  • Modernizr
    Javascript Libraries
  • jQuery
    Javascript Libraries
  • PHP
    Programming Languages
  • Bootstrap
    UI Frameworks
  • Google Analytics
    Web Analytics

Media & News

ImmusanT, Inc.'s Email Address Formats

ImmusanT, Inc. uses at least 1 format(s):
ImmusanT, Inc. Email FormatsExamplePercentage
First.Last@immusant.comJohn.Doe@immusant.com
41%
First@immusant.comJohn@immusant.com
9%
Last@immusant.comDoe@immusant.com
9%
First.Last@immusant.comJohn.Doe@immusant.com
41%

Frequently Asked Questions

Where is ImmusanT, Inc.'s headquarters located?

Minus sign iconPlus sign iconImmusanT, Inc.'s main headquarters is located at One Kendall Square Cambridge, MA 02139 US. The company has employees across 1 continents, including North America.

What is ImmusanT, Inc.'s phone number?

Minus sign iconPlus sign icon You can contact ImmusanT, Inc.'s main corporate office by phone at
+1-617-299-****
. For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is ImmusanT, Inc.'s official website and social media links?

Minus sign iconPlus sign iconImmusanT, Inc.'s official website is immusant.com and has social profiles on LinkedIn.

How much revenue does ImmusanT, Inc. generate?

Minus sign iconPlus sign icon As of September 2019, ImmusanT, Inc.'s annual revenue is estimated to be $495K.

What is ImmusanT, Inc.'s SIC code NAICS code?

Minus sign iconPlus sign iconImmusanT, Inc.'s SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does ImmusanT, Inc. have currently?

Minus sign iconPlus sign iconAs of September 2019, ImmusanT, Inc. has approximately 18 employees across 1 continents, including North America. Key team members include Chief Scientific Officer: R. A.Managing Partner: W. W.Vice President, Clinical Operations & Project Management: K. N.. Explore ImmusanT, Inc.'s employee directory with LeadIQ.

What industry does ImmusanT, Inc. belong to?

Minus sign iconPlus sign iconImmusanT, Inc. operates in the Biotechnology Research industry.

What technology does ImmusanT, Inc. use?

Minus sign iconPlus sign iconImmusanT, Inc.'s tech stack includes Font Awesomeyepnope.jsOWL CarouselModernizrjQueryPHPBootstrapGoogle Analytics.

What is ImmusanT, Inc.'s email format?

Minus sign iconPlus sign iconImmusanT, Inc.'s email format typically follows the pattern of First.Last@immusant.com. Find more ImmusanT, Inc. email formats with LeadIQ.

How much funding has ImmusanT, Inc. raised to date?

Minus sign iconPlus sign icon As of September 2019, ImmusanT, Inc. has raised $52M in funding. The last funding round occurred on Jan 01, 2017 for $40M.

When was ImmusanT, Inc. founded?

Minus sign iconPlus sign iconImmusanT, Inc. was founded in 2010.

ImmusanT, Inc.

Biotechnology ResearchMassachusetts, United States11-50 Employees

ImmusanT is a privately held biotechnology company focused on protecting patients with celiac disease against the effects of gluten. By harnessing new discoveries in immunology ImmusanT aims to improve diagnosis and medical management of celiac disease byprotecting against the effects of gluten exposure while patients maintain a gluten free diet. The company is developing Nexvax2®, a therapeutic vaccine for celiac disease, and diagnostic and monitoring tools to improve celiac disease management. ImmusanT’s targeted immunotherapy discovery platform can be applied to a variety of autoimmune diseases. Founded in 2010, ImmusanT is backed by Vatera Healthcare Partners. More information may be found at www.ImmusanT.com, or follow @ImmusanT on Twitter.

Section iconCompany Overview

Headquarters
One Kendall Square Cambridge, MA 02139 US
Phone number
+1-617-299-****
Website
immusant.com
SIC Code
8733 - Noncommercial Research Organizations
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2010
Employees
11-50

Section iconMedia & News

Section iconFunding & Financials

  • $52M

    ImmusanT, Inc. has raised a total of $52M of funding over 2 rounds. Their latest funding round was raised on Jan 01, 2017 in the amount of $40Mas a financing.

  • $1M

    ImmusanT, Inc.'s revenue is estimated to be in the range of $1M

Section iconFunding & Financials

  • $52M

    ImmusanT, Inc. has raised a total of $52M of funding over 2 rounds. Their latest funding round was raised on Jan 01, 2017 in the amount of $40Mas a financing.

  • $1M

    ImmusanT, Inc.'s revenue is estimated to be in the range of $1M

Company Leadership

  • Stylized image of a person
    R. A.
    Chief Scientific Officer
    Phone icon
    Mobile Phone
  • Stylized image of a person
    W. W.
    Managing Partner
    Phone icon
    Mobile Phone
  • Stylized image of a person
    K. N.
    Vice President, Clinical Operations & Project Management
    Phone icon
    Mobile Phone
  • Stylized image of a person
    H. H.
    Clinical Project Director
    Phone icon
    Mobile Phone
  • Stylized image of a person
    S. W.
    Director, Assay Development
    Phone icon
    Mobile Phone

Employee Directory

  • Stylized image of a person
    M. S.
    Office Manager
    Phone icon
    Mobile Phone
  • Stylized image of a person
    T. K.
    Member Board Of Directors
    Phone icon
    Mobile Phone

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust LeadIQ to help them build pipeline confidently.

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.